Safety of Tofacitinib in the COVID-19 Pandemic-Enough Is Not Enough
Inflamm Bowel Dis
.
2021 Jul 27;27(8):e89.
doi: 10.1093/ibd/izab051.
Authors
Philipp A Reuken
1
,
Niels Teich
2
,
Andreas Stallmach
1
Affiliations
1
Department of Internal Medicine IV, Jena University Hospital, Jena, Germany.
2
Internistische Gemeinschaftspraxis für Verdauungs und Stoffwechselkrankheiten Leipzig und Schkeuditz, Leipzig, Germany.
PMID:
33783508
PMCID:
PMC8083615
DOI:
10.1093/ibd/izab051
No abstract available
Publication types
Editorial
Comment
MeSH terms
COVID-19*
Humans
Pandemics*
Piperidines
Pyrimidines / adverse effects
SARS-CoV-2
Substances
Piperidines
Pyrimidines
tofacitinib
Grants and funding
Abbvie, Astellas, Celltrion, Falk Foundation, Ferring, Janssen, MSD, Recordati Pharma, and Takeda